Values First Advisors, Inc. Sage Therapeutics, Inc. Transaction History
Values First Advisors, Inc.
- $182 Million
- Q3 2024
A detailed history of Values First Advisors, Inc. transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Values First Advisors, Inc. holds 27,947 shares of SAGE stock, worth $144,485. This represents 0.11% of its overall portfolio holdings.
Number of Shares
27,947
Previous 28,962
3.5%
Holding current value
$144,485
Previous $314,000
35.99%
% of portfolio
0.11%
Previous 0.19%
Shares
9 transactions
Others Institutions Holding SAGE
# of Institutions
198Shares Held
46.5MCall Options Held
402KPut Options Held
209K-
Vanguard Group Inc Valley Forge, PA5.76MShares$29.8 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.59MShares$28.9 Million0.64% of portfolio
-
Black Rock Inc. New York, NY5.22MShares$27 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.46MShares$23.1 Million0.54% of portfolio
-
State Street Corp Boston, MA2.93MShares$15.1 Million0.0% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $307M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...